title: The diagnosis and management of lower urinary tract symptoms in multiple sclerosis patients.
abstract: Sixty-five percent of multiple sclerosis patients have moderate to severe urinary symptoms and up to 14% initially present with urinary symptomatology. Urinary retention, neurogenic detrusor overactivity, and detrusor sphincter dyssynergia, all increase the risk for urinary tract infections in patients with multiple sclerosis, and these infections may exacerbate their immune response, leading to symptom progression. Fewer than half of the patients with urinary symptoms have seen a specialist and only half have been treated for their neurogenic detrusor overactivity. Several treatments including pelvic floor muscle therapy, pelvic floor electrical stimulation, anticholinergics, desmopressin, sacral nerve neuromodulation, posterior tibial nerve stimulation, cannabinoids, and intravesical therapy with vanniloids, as well as botulinum toxin, have all been shown to be effective in treating urinary symptoms in those with multiple sclerosis. Clean intermittent catheterization is invaluable in patients with persistent urinary retention to avoid infection and upper tract dysfunction. Indwelling transurethral catheterization should be avoided because of the high risk of infection. Identification and successful treatment of these urinary conditions will improve the health and quality of life for these men and women.
authors.forename: Peter K
authors.initials: PK
authors.lastname: Sand
authors.forename: Robert I
authors.initials: RI
authors.lastname: Sand
mesh_terms: D002986:Clinical Trials as Topic; D003950:Diagnostic Techniques, Urological; D019468:Disease Management; D005260:Female; D006801:Humans; D059411:Lower Urinary Tract Symptoms / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology / Q000503:physiopathology / Q000523:psychology; D008297:Male; D054539:Medication Therapy Management; D009103:Multiple Sclerosis / Q000150:complications / Q000453:epidemiology; D009465:Neuromuscular Agents / Q000627:therapeutic use; D011788:Quality of Life; D012307:Risk Factors; D063189:Symptom Assessment / Q000379:methods*; D014551:Urinary Tract / Q000473:pathology / Q000503:physiopathology; D014570:Urologic Diseases / Q000209:etiology / Q000628:therapy
chemical_list: D009465:Neuromuscular Agents